Navigation Links
PharmAthene Reports Year-End 2012 Financial And Operational Results
Date:3/13/2013

er of 2012.

Operating ExpensesResearch and development expenses in 2012 were $19.5 million, compared to $21.2 million in 2011.  Research and development expenses decreased primarily as a result of a reduction in the Company's indirect operating expenses and direct costs for the Valortim® program, partially offset by higher direct SparVax® program expenses.

Expenses associated with general and administrative functions decreased to $11.6 million from $14.3 million for the years ended December 31, 2012 and 2011, respectively. The decrease in general and administrative expense in 2012 was primarily the result of a reduction in legal and other general and administrative expenses, partially offset by a one-time insurance recovery.

Net LossFor the year ended December 31, 2012, PharmAthene's net loss was $4.9 million, or $0.10 per share, compared to a net loss of $3.8 million, or $0.08 per share, for the year ended December 31, 2011. The increase in net loss primarily consists of a reduction in other income/expenses of $6.4 million associated with the change in the fair value of the Company's derivative instruments, offset by a decrease in operating expenses of $4.5 million.

Cash and Accounts ReceivableAs of December 31, 2012, the Company had cash and cash equivalents, restricted cash, and U.S. government accounts receivable and unbilled accounts receivable totaling approximately $19.2 million, compared to $18.8 million as of December 31, 2011. The year-over-year difference was primarily a result of cash used in operations, offset by funding provided under a term loan and revolving line of credit with GE Capital, which was completed in the first quarter of 2012.

Conference Call and Webcast InformationPharmAthene management will be hosting a conference call to discuss the Company's year-end 2012 financial and operational results. The call is scheduled to begin at 4:30 pm Eastern Time on Wednesday,
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
2. PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
3. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
4. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
5. PharmAthene Reports First Quarter 2012 Financial Results
6. PharmAthene Reports Third Quarter 2012 Financial Results
7. PharmAthene To Present At The Noble Financial 9th Annual Equity Conference On Tuesday, January 22, 2013
8. PharmAthene To Host Year-End 2012 Conference Call And Webcast On Wednesday, March 13, 2013
9. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
10. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
11. Interleukin Genetics Reports Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... "In America," the popular news television program that airs ... by legendary film actor James Earl Jones, has announced that ... segment. , Botany is commonly described as the scientific ... a bit more complicated than that. Scientists and other professionals ... from the smallest bacteria known to man to the largest ...
(Date:3/25/2015)... Agnition announced today that it will be featured ... the first time at 7:30 a.m. CST March 31 ... the extremely important role soil microbes perform in crop ... Catalyst™ technology that enhances soil and plant health for ... again on April 28. , A biochemist at Agnition ...
(Date:3/25/2015)... , March 25, 2015  S&P Capital ... Factual Stock Report coverage on Abattis Bioceuticals ... ATTBF; CSE: ATT): is a specialty biotechnology company ... cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, ... in North America . The ...
(Date:3/25/2015)... UK (PRWEB) March 25, 2015 An ... natural ingredients in all forms of food nutrients, regulatory ... to a substantial rise in demand for natural astaxanthin ... have started to ramp up their capacities to satisfy ... both natural and synthetic source astaxanthin (used in nutraceuticals, ...
Breaking Biology Technology:Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2
... help emerging and mid-size biopharmaceutical companies address an ... International (NASDAQ: PRXL ), a ... it is introducing a series of executive briefings ... these forums, PAREXEL will discuss how a spectrum ...
... Silence Therapeutics plc (AIM: SLN) ("Silence" or the ... company, today announces that application has been sought for 530,000 ... be admitted to trading on AIM. The new Ordinary Shares ... Dr. Philip Haworth, former Chief Executive Officer of Silence. ...
... Ind. ╨ Engineers have discovered details about the behavior of ... manufacturing, diagnostics and other research., ... surface textures in metals, ceramics and other materials for applications ... pulse at durations of 100 femtoseconds, or quadrillionths of a ...
Cached Biology Technology:PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes 2PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes 3PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes 4Silence Therapeutics Additional Listing 2Silence Therapeutics Additional Listing 3Research could improve laser-manufacturing technique 2
(Date:3/17/2015)... Minn. , March 17, 2015 ... technology company specializing in clinical study management systems, ... be in attendance at ARENA,s Outsourcing in Clinical ... NC.  This event provides an excellent forum for ... easy-to-use, flexible and affordable software-as-a-service (SaaS) eClinical technology ...
(Date:3/12/2015)... FAIRFAX, Va. , March 12, 2015 ... company and a member of the Texas Instruments Design ... Chandrababu Naidu has demonstrated its IriShield USB MK2120U ... iris scanning facility for pension distribution. ... and assembled to be marketed in India ...
(Date:3/11/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/3p32qm/access_control ) has ... by Product, Application & By Geography - Global Forecast ... , This report predicts that the access ... 2020, with an estimated CAGR of 10.6%. ... such as contact cards & readers, contactless cards & ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2
... close attention to the state of the snow on ... snow-watchers looking closely at a South Pole snowfield this ... the UK,s National Physical Laboratory (NPL) are examining an ... largest inter-comparison between satellite sensors. The results ...
... -- The official State Dinosaur of Texas is up for ... proved the titleholder has been misidentified. State Rep. Charles ... change the name of the state dinosaur from Pleurocoelus ... massive sauropod ,whose tracks and bones litter the central Texas ...
... New Rochelle, NY, January 12, 2009The Academy of Breastfeeding ... be well advised to review its policy banning photographs ... that breastfeeding is an unseemly bodily function best kept ... has no place in contemporary society. It further perpetuates ...
Cached Biology News:Satellites search out South Pole snowfields 2A case of mistaken dino-identity 2
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
CD69/CD3 50 tests...
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Rabbit polyclonal to pCrosstide (HRP) ( Abpromise for all tested applications)....
Biology Products: